Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts by O’Donnell, Robert T. et al.
ORIGINAL ARTICLE
Dose, timing, schedule, and the choice of targeted epitope alter
the efﬁcacy of anti-CD22 immunotherapy in mice bearing
human lymphoma xenografts
Robert T. O’Donnell Æ Yunpeng Ma Æ
Hayes C. McKnight Æ David Pearson Æ
Joseph M. Tuscano
Received: 16 November 2008/Accepted: 16 April 2009/Published online: 13 May 2009
 The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract CD22 is a cell-surface adhesion molecule on
most B-cell NHL, so it is a promising target for immuno-
therapy. HB22.7 is an anti-CD22 mAb that binds the two
NH2-terminal immunoglobulin domains and speciﬁcally
blocks the interaction of CD22 with its ligand. CD22-
blocking mAbs induce apoptosis in neoplastic B-cells and
are functionally distinguishable from other anti-CD22
mAbs. This study assessed the optimal dose, route, sche-
dule, and the targeted CD22 epitope. Raji NHL-bearing
nude mice were studied. A non-blocking anti-CD22 mAb
(HB22.27) was used as a control. HB22.27 had minimal
effect, whereas HB22.7 improved survival and shrank
tumors substantially. HB22.7 doses greater than 1.4 mg/
week did not further increase efﬁcacy (or toxicity). Tumors
less than 200 mm
3 had a higher response rate than did
larger tumors. Various schedules of HB22.7 administration
were tested; one dose every other week was more effective
than more or less frequent dosing. Pharmacokinetic studies
revealed that the half-life of HB22.7 was 28 days; this
correlated with the time needed to re-populate cell-surface
CD22 after treatment with HB22.7. Immuno-PET showed
that NHL was rapidly and speciﬁcally targeted by copper-
64-labeled-HB22.7. This study provided data as to an
optimal dose, route, schedule and interval between doses of
HB22.7.
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Introduction
NHL is the sixth most common cause of cancer-related
deaths in the United States. Standard therapy relies on toxic
drugs which, while initially effective, are curative in less
than 50% of cases. Rituximab, a chimeric anti-CD20 mAb
has become integral to many drug regimens for NHL
therapy [1]. Because of the safety and efﬁcacy of targeted
mAb like rituximab, new antibodies are being tested to see
if they may also be effective, synergistic with rituximab, or
useful when the NHL becomes resistant to other therapies.
CD22 is a B-lymphocyte-speciﬁc glycoprotein and
adhesion molecule found on the outer surface membrane of
nearly all mature B-cells. Most NHL express CD22 as well,
so CD22 is a promising target for immunotherapy [2, 3].
CD22 is a member of the immunoglobulin superfamily,
with an extracytoplasmic component that contains seven
immunoglobulin-like domains. The two amino-terminal
domains of CD22 mediate adhesion to sialic acid bear-
ing ligands and can bind multiple hematopoietic cell types
[4–6].
A panel of anti-CD22 mAbs that targets CD22 was
evaluated [6]. Few studies have examined the clinical or
pre-clinical effects of mAb binding to different epitopes
of the same receptor. Anti-CD22 mAbs that bind the
two NH2-terminal immunoglobulin domains of CD22 and
speciﬁcally block the interaction of CD22 with its ligand
were identiﬁed. These ‘‘blocking’’ mAbs induce apoptosis
in neoplastic B-cells [4]. Studies that eliminated the ﬁrst
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binding of these domains to their ligands was critical for
B-cell survival [7]. By contrast, mAbs that do not block
ligand binding have only modest functional effects [8, 9].
Ligand blocking anti-CD22 mAbs (e.g. HB22.7) are unique
and functionally distinguishable from other anti-B-cell, and
even other anti-CD22 mAb. Consistent with this data, the
blocking anti-CD22 mAbs are more effective than non-
blocking mAb at initiating CD22-mediated signal trans-
duction in general, and the stress activated protein kinase
(SAPK) pathway speciﬁcally [5, 8, 9]. We characterized
several anti-CD22 mAbs that have unique signaling prop-
erties, pro-apoptotic effects, and lymphomacidal proper-
ties; based on these properties HB22.7 was chosen for
further development [10]. HB22.7 has recently been
humanized (hHB22.7) and has the potential to become an
exciting, new treatment for NHL.
Other effective mAb have entered the clinical realm
without much preclinical data to show what may be the
most effective dose, interval between doses, route of
administration, or the effect of other critical factors such as
tumor size. In addition, other anti-CD22 mAbs have been
evaluated in human clinical trials and demonstrated only
modest efﬁcacy [11]. These anti-CD22 mAbs bind to a
different epitope than does HB22.7, do not block ligand
binding, and do not have functional effects [12]. The goal
of this study is to characterize the dose, schedule, CD22
epitope, and tumor related factors that can guide the
translation of the hHB22.7 toward a human clinical trial.
Methods
Cell culture
The Raji human NHL cell line (ATCC) was maintained in
RPMI (GIBCO, Gaithersburg, MD) with 10% v/v fetal
bovine serum (FBS) (Cambrex, Baltimore, MD) supple-
mented with glutamine, penicillin and streptomycin. For the
in vitro studies, cells were cultured in 225 cm ﬁlter vented
ﬂasks. Cells were maintained in a humidiﬁed tissue culture
incubator at 37Cw i t h5 %C O 2 split every 2–3 days.
Monoclonal antibodies
HB22.7 and HB22.27 were puriﬁed from ascites (Covance,
Princeton, NJ) and have been previously characterized [6].
HB22.7 pharmacokinetics
A FACS-based assay was used to serially measure the
concentration of HB22.7 in the serum of mice bearing Raji
xenografts after a single intravenous (IV) dose (1.4 mg).
To establish a standard curve, mouse serum with known
concentrations of HB22.7 were used for FACS analysis of
the Raji cell line. Concentrations of directly FITC-conju-
gated HB22.7 were plotted against mean ﬂuorescence
intensity (MFI) compensating for background effects of
unstained Raji cells and mouse serum. A linear relationship
was observed between 0.2 and 2.0 lg HB22.7/cc and MFIs
between 100 and 600. To avoid the potential confounding
effects of CD22 saturation, the MFIs within this range were
used to calculate the serum concentration of HB22.7 after
treatment. Serum samples were obtained from the tail vein
at baseline and at indicated intervals after treatment.
Mouse experiments
Nude mice bearing human xenografts from the Raji NHL
cell line has proven utility for evaluating the efﬁcacy of new
treatments [10]. To prevent rejection and ensure tumor
implantation, nu/nu mice on a Balb/c background (Harland
Laboratories, Indianapolis, IN) received whole body irra-
diation (400 rad) with a 6 MeV beam from the linear
accelerator. Radiation before xenograft implantation was
shown to be a useful technique in this model and has been
used in all our prior murine studies. After 3 days, mice were
injected subcutaneously with 3–6 9 10
6 Raji NHL cells in
media(100 ll).In2–3 weeks,tumorsreachedanacceptable
size for treatment assessment (20–300 mm
3) [41, 42]. In
some experiments, treatment with the mAb was done 1 day
after the xenograft was implanted rather than in established
tumors. All mice were injected with mAb IV though the tail
vein except for the immuno-positron emission tomography
(iPET) experiment.IntheiPET experiments,mice were also
injected subcutaneously (SQ) or intraperitoneally (IP).
Mice were assessed for toxicity by twice-weekly mea-
surement of their weight, activity, and blood counts for the
ﬁrst 28 days, then weekly for the rest of the 84-day study
period (standard assessment of toxicity by the UC Davis
School of Veterinary Medicine Lab Animal Clinic). Tumor
diameter was assessed in three dimensions using calipers
and the volume calculated by the ellipsoid volume equation
(d1 9 d2 9 d3 9 0.52 = ellipsoid volume). Tumoricidal
effects were assessed by twice weekly tumor volume
measurement. Tumor responses will be categorized as
follows: cure (C, tumor disappeared and did not re-grow by
the end of the 84-day study); complete regression (CR,
tumor disappeared for at least 7 days but later re-grew);
partial regression (PR, tumor volume decreased by 50% or
more for at least 7 days then re-grew).
Statistical analysis
Differences in response among treatment groups were
evaluated using the Kruskal Wallis rank sum test. Survival
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animal was sacriﬁced due to tumor-related causes, the last
volume was carried forward and used in the analysis of
later time points. Analysis of variance was used to test for
differences among treatment groups. P values are two-
tailed and represent the nominal P values. Protection for
multiple comparisons is provided by testing only within
subsets of groups found to be statistically signiﬁcantly
different.
I-PET
Copper-64 labeled HB22.7 was used to determine the ability
of HB22.7 to speciﬁcally target NHL in vivo [13].
64Cu
(a positron emitter) combines all three modes of decay: elec-
troncapture(41%),beta-(40%)andbeta?(19%)makingita
useful radionuclide for both imaging and therapy.
64Cu was
produced on the biomedical cyclotron at Washington Uni-
versityandsuppliedas
64CuCl2(0.1 MHCl).Thebifunctional
chelating agent, DOTA (1, 4, 7, 10-tetraazacyclododecane
N,N0,N00,N000-tetraacetic acid (DOTA) contains a reactive
functionality to form a covalent attachment to proteins and a
strong metal-binding group to chelate radiometals [14].
DOTA-HB22.7 was prepared by incubation with DOTA-
NHS-ester at pH 5.5. DOTA-HB22.7 was labeled with
64Cu-
acetate in 0.1 M ammonium acetate, pH 5.5. After incubation
1 mM EDTA terminated the reaction. HPLC puriﬁcation was
then performed to purify the
64Cu-DOTA-HB22.7.
PET scanning was performed using a microPET II
small-animal scanner [15, 16], a system that reconstructs
images with a spatial resolution of approximately 1.2 mm
using conventional analytic reconstruction algorithms. The
resolution is quite isotropic at the center of the ﬁeld of
view, resulting in a resolution volume of 1.7 mm
3. The
absolute sensitivity of the scanner at the center of the ﬁeld
of view is 2.25% using the default energy window settings
of 250–750 keV and a coincidence timing window of
10 ns. The imaging ﬁeld of view of the scanner is 10 cm in
the transverse direction and 4.8 cm in the axial direction.
High quality images were obtained using injected doses of
100 lCi and imaging times of 5–10 min.
Mice were anesthetized with isoﬂurane induction and
maintenance during imaging and monitored visually
throughout the study. A scavenging system trapped exhaled
anesthetic gas. Mice were injected with approximately
200 lCi (range 198–216 lCi) of
64Cu-DOTA-HB22.7 in
160 ll saline by one of three routes: IV via the tail vein, IP
on the right ﬂank, or SQ between the shoulders (n = 3 per
route of administration). The activity in the syringe before
and after injection was measured in a dose calibrator and
decay-corrected so that the injected dose was known. At
the moment of radiotracer injection, data acquisition was
initiated in list mode on the microPET II scanner. Imaging
continued for 90 min or until sufﬁcient counts were
recorded. Then, the list mode data was binned into time
frames and reconstructed with a statistical 3D reconstruc-
tion algorithm [16]. Absolute quantiﬁcation was achieved
by calibrating the mouse images with the image of a
cylinder containing a uniform concentration of positron-
emitting radionuclide with a similar geometry and volume
as a mouse. The calibration scan was acquired under
identical conditions and reconstruction parameters as the
mouse scans and has similar attenuation and scatter char-
acteristics. Quantiﬁcation with this method, without scatter
and attenuation correction was better than 10% when
comparing contralateral sites in the same mouse or the
same site across different mice of similar weight. Image
analysis was carried out using ASIPro software and
in-house IDL-based tool for deﬁning and quantifying
uptake in volumes of interest.
Results
In previous experiments that established the preclinical
efﬁcacy of HB22.7, a single dose of HB22.7 (1.4 mg) was
administered IV [10]. In the current study, the 1.4 mg dose
was compared to higher single HB22.7 doses to see if an
even better response could be obtained, Fig. 1. The choice
of 1.4 mg was based on the equivalent dose that effectively
induced apoptosis in vitro, the equivalent dose of rituximab
(with dosage adjustments for the increased surface area in
mice as compared to humans), and the dose previously
shown to have efﬁcacy in mice bearing Raji xenografts.
Although the single 4.2 mg dose produced a slightly lower
peak tumor volume than did the 1.4 or 2.8 mg doses, the
results of treatment with any single dose of HB22.7 were
similar to each other but greatly different than the pattern
of disease progression seen in the untreated controls.
Figure 1 showed that 1.4 mg of HB22.7 was sufﬁcient to
cause tumor shrinkage and that higher doses were no more
effective. A one-way ANOVA showed that all HB22.7
treatment doses resulted in signiﬁcant tumor shrinkage
when compared to the control P\0.001; none of the
HB22.7 doses were signiﬁcantly different from each other,
P[0.05. As is characteristic of this model, some untreated
mice had spontaneous partial responses. For Fig. 1, 26% of
untreated mice had spontaneous PR, but the RR for mice
treated with only one dose of HB22.7 was 53% and 7% of
the responses were complete.
Multiple studies were performed using HB22.7 to treat
nude mice bearing Raji xenografts. Similar to what is seen
after treatment with rituximab, it was observed that some
mice had CRs but some mice did not respond at all. One
factor that related to the response and survival was the size
of the initial tumor, Fig. 2. HB22.7 was much more
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123effective when the initial size of the tumor was less than
200 mm
3. The CR rate, tumor volume reduction, and sur-
vival were all better when tumors were less than 200 mm
3
at the time of HB22.7 administration. In this experiment,
untreated controls had a spontaneous remission rate of 5%
(one PR). Mice with tumors less than 200 mm
3 when
treated with one dose of HB22.7 had a 48% RR (33% CRs
and 15% PRs), in addition to ﬂattening of the tumor growth
rate. Mice with tumors greater than 200 mm
3, when treated
with one dose of HB22.7 had no shrinkage that qualiﬁed
for even a PR (although their growth rate slowed). The
difference between response rates for small tumors versus
untreated controls was signiﬁcant (P = 0.012), however,
there was no signiﬁcant difference between the response
rate of untreated controls and mice bearing xenografts
greater than 200 mm
3. Similarly, the difference in CRs
between the small treated xenografts and untreated controls
was P = 0.015.
The concept of treating relatively low-volume tumors
was tested further. Mice were treated with HB22.7
(1.4 mg) 1 day after the implantation of the Raji cells;
mice were followed for development of a tumor, its growth
kinetics, and survival, Fig. 3. Early treatment (low tumor
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Fig. 3 The effect of dosing schedule on tumor response rate. Groups
of nine mice were treated with HB22.7 before Raji NHL tumors had
become established. HB22.7 (1.4 mg) was administered on: Day 1,
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12 weeks, or were untreated. Mice were monitored for tumor volume
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123volume, non-established tumors) was at least as effective as
the same dose and schedule of HB22.7 given to mice with
small established tumors, Fig. 2. The CR rate for all mice
treated with HB22.7 in this experiment was 9/27 (33%),
similar to mice with small established tumors that were
treated with HB22.7, see Fig. 2.
Most therapies for NHL are given more than one time.
There is no prior data to assess the response rate produced
by HB22.7 in a mouse model when it is given in multiple
doses and with differing schedules of administration. Fig-
ure 3 shows that multiple doses result in more tumor
shrinkage than did one dose. Thirty-seven percent of mice
treated with more than one dose had a CR, whereas 11% of
mice treated with one dose had a CR; none of the untreated
control mice had a spontaneous CR. For the response rate
data, the P values for administration of HB22.7 weekly
versus the untreated control, and once every other week
versus the untreated control, were 0.043 and 0.011,
respectively. All other comparisons did not reach statistical
signiﬁcance, although the P value for one single adminis-
tration of HB22.7 versus the control was 0.06. However,
the interval between doses was also important as indicated
by the better tumor shrinkage when HB22.7 was given
every other week for six doses, compared to weekly
administration of HB22.7 for 6 consecutive weeks, Fig. 6a.
The survival of mice treated every other week with HB22.7
was signiﬁcantly better than the untreated control (Fig. 3c),
and the response rate was higher for mice treated every
other week as well. For survival, the only signiﬁcantly
different comparison was for HB22.7 administration once
every other week versus the untreated control; P = 0.026.
The best interval between doses studied was 2 weeks.
It has been well described that the binding of CD22 by
mAb mediates internalization; CD22 reappearance at the
cell surface does not occur until the levels of anti-CD22
nadir [12, 17]. To determine if the in vivo HB22.7 half-life
and the xenograft’s CD22 cell surface expression were
related, a FACS-based assay to measure HB22.7 levels was
used. This revealed that after a single 1.4 mg dose, HB22.7
did not go below 0.5 ug/ml for 14 days and below 0.4 ug/ml
for nearly 30 days. The measured half-life of HB22.7 was
28 h, Fig. 4. To assess for changes in CD22 surface
expression in the NHL xenografts after treatment, ﬁne nee-
dle aspirations (FNA) were done serially; the samples were
examined by ﬂow cytometry for CD22 surface expression.
This analysis revealed that CD22 became internalized
quickly, within 6 h of treatment and did not return to base-
line surface expression levels for 14 days, Fig. 5.
Studies that examine the clinical effects of speciﬁc
CD22 epitope binding have not been done previously.
HB22.7 binds to domain 2 of CD22 and blocks ligand
binding [4–6]. We conducted a xenograft study comparing
the efﬁcacy of HB22.7 to that of HB22.27 (which binds to
domain 3) [6]. Figure 6 shows that the non-blocking anti-
CD22 mAb (HB22.27) did not result in as much tumor
shrinkage as did the blocking anti-CD22 mAb, HB22.7.
The overall response rate for mice treated with HB22.7 was
84%; the overall response rate for the mice treated with
HB22.27 was 41%, P\0.0001. There were twice as many
PRs and twice as many CRs in the HB22.7 group than in
mice treated with HB22.27. This translated into improved
overall survival with 85% alive at the end of the 12 week
study after treatment with HB22.7 versus 42% after treat-
ment with HB22.27.
Previous studies demonstrated excellent targeting of
Raji xenografts by indium-111-DOTA-HB22.7 after IV
injection [10]. However, micro-PET scanning offers a
greater resolution and sensitivity than gamma camera
imaging of indium-111 and iPET allows for real-time in
vivo targeting and biodistribution studies [18–20], there-
fore we tested
64Cu-DOTA-HB22.7. Many experimental
Fig. 4 HB22.7 half-life in mice bearing Raji xenografts. FACS was
used to measure the concentration of HB22.7 after administration of a
single 1.4 mg dose. The analysis was repeated three times; error bars
represent the standard deviation
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123agents are administered IV via the tail vein; this can be
difﬁcult and irreproducible, especially after repeated
injections in the same animal for longitudinal studies.
Easier and more reproducible methods of administration
would be useful provided that tumor targeting and biodis-
tribution are not adversely altered. There are no studies that
compare targeting after different routes of anti-CD22
radiopharmaceutical administration. Using copper-64 as
a positron emitter it was shown by iPET scanning with
64Cu-DOTA-HB22.7 that HB22.7 could target Raji-NHL
using the usual route (IV), but also by SQ or IP injection,
Fig. 7. These images show that each route of administration
resulted in excellent tumor targeting by 48 h after injection.
The background was low indicating good speciﬁcity and
there was non-speciﬁc targeting of non-NHL tissue.
Discussion
Recent studies have examined the role of the CD22 ligand
binding domain in normal and malignant B-cell survival.
Murine models were used to demonstrate that the CD22
ligand binding domain is critical for normal B-cell sur-
vival. It was conclusively shown that mAbs that block
CD22 ligand binding inhibit survival in vivo. Mouse anti-
mouse CD22 ligand blocking mAbs that eradicated lym-
phoma independent of complement and Fc receptor-bearing
effector cells have been developed [21, 22].
This study examined the optimal dose, interval, and
route of administration of HB22.7. In addition, the effects
of initial tumor volume and CD22 epitope binding were
examined. A safe and effective dose of HB22.7 was
1.4 mg; above that dose further improvement in efﬁcacy
was not demonstrable. However, this could change with
variations in tumor burden and dosing intervals. Recent
patient-speciﬁc dosing studies with rituximab have con-
ﬁrmed variable serum levels in patients likely due to their
differing tumor burdens and antigen densities [23]. A dose
escalation study is still needed to determine the optimal
dose in humans, however, this study provides good insight
into the appropriate starting dose for human clinical trials.
There are two distinct ways to initiate treatment in this
model. First, treatment can be done on established tumors.
This method has the advantage of having measurable dis-
ease and knowing that the tumor did in fact grow in a
particular mouse. The downside of this choice is that we
conclusively showed that larger tumors have a lower
response rate so small differences in the tumor size may
obscure the results. It is important to note, but not unex-
pected, that larger tumors do not respond well. These data
suggest that pretreatment with other agents to reduce tumor
bulk prior to treatment with anti-CD22 mAb would be a
valid strategy. Also, since the tumors are already large and
growing when treatment is initiated, there is less time for
the therapy to work before the mice need to be euthanized.
The other way to initiate treatment is to give the ﬁrst dose
of mAb on the day after the NHL cells have been implanted
to form the xenograft. At this point, all mice will have been
injected with the same number of cells so their starting
point is more homogeneous as the implanted cells have not
had a chance to grow at different rates, or to different sizes.
Because the xenograft is then at its smallest, the mAb will
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123be able to target it optimally. We demonstrated that
differences between experimental groups and the controls
were easier to detect when the mAb therapy was given on
the day after xenograft implantation rather than on estab-
lished tumor. This mimics treatment of non-bulky tumors
or minimal residual disease. In some ways, it is not sur-
prising to ﬁnd that smaller tumors have a better response
rate than large ones, and that tumors that are found early
(the analogy for treating the mice 1 day after xenograft
implantation) are easier to treat than those that are well
established. However, this is indeed a relevant topic that
directly relates to humans receiving immunotherapy. For
example, a mAb that is efﬁcacious in low tumor-volume
settings may have an important role in clearing the bone
marrow of residual malignant cells. Another role could be
related to eliminating foci of NHL in association with stem
cell harvest or bone marrow transplantation. Clinical trials
will be needed to further explore this topic in patients.
Previous studies with epratuzumab showed that nearly
80% of CD22 was internalized due to prolonged mAb
binding [12]. Based on this ﬁnding, we hypothesized that
closely spaced doses would not signiﬁcantly improve
efﬁcacy because of ‘‘loss of target’’ (CD22) due to its
internalization. Increasing the interval between doses may
allow for return of CD22 surface expression. In this study,
giving six doses of HB22.7 every other week was the most
effective schedule; better than six consecutive weekly
doses. We demonstrated that the CD22 surface expression
on the implanted Raji xenografts was lost within 6 h of
treatment and did not return for nearly 14 days. This cor-
related with a prolonged HB22.7 half-life and validates our
hypothesis that receptor saturation by HB22.7 results in a
loss of target and diminished efﬁcacy. This is likely
because the target of HB22.7 (CD22) was saturated by
weekly doses mediating CD22 internalization, thus making
weekly dosing irrelevant. Six doses of HB22.7 every other
week likely results in a more prolonged therapeutic level of
HB22.7 when the target CD22 is present leading to
improved efﬁcacy.
The iPET experiments demonstrated that radiolabeled
HB22.7 would speciﬁcally target NHL in vivo with low
background (non-speciﬁc binding). This data is useful in
that it showed that the SQ and IP doses, which are easier
and more reproducible to administer to mice than is IV,
were a valid experimental technique. While the vast
majority of mAb-based therapeutics are administered IV,
some have been administered SQ [24] without data
assessing the equivalency of targeting and pharmaco-
kinetics. Thus, this data may facilitate the translation of
humanized HB22.7 to human clinical trials.
The control antibody, HB22.27 binds CD22 as well as
HB22.7 does; however, they bind different epitopes. Our
previous studies show that binding to the correct epitope
(as does HB22.7) initiates a signaling cascade that can
cause apoptosis in NHL cells [8, 9]. As well, other studies
have shown that the ﬁrst two domains of CD22 are critical
for B-cell survival [7] and mouse derived anti-mouse, anti-
CD22 mAbs that are directed at CD22 ligand blocking
domains eradicate murine NHL [23]. Data presented here
show that there is a great difference in efﬁcacy when the
appropriate CD22 epitope is targeted. Other anti-CD22
mAb have been studied and have not generated signiﬁcant
responses in animal models or human clinical trials [11,
12] likely because they, like HB22.27 bind to a non-ligand
blocking region of CD22. This is one of the ﬁrst studies
that clearly shows that the speciﬁc epitope bound by a mAb
effects efﬁcacy.
This study showed that 1.4 mg of HB22.7 was an
appropriate dose upon which to base further clinical stud-
ies. Treatment of small and/or early tumors resulted in
better efﬁcacy than did treatment of large established
tumors. An every other week schedule of HB22.7 admin-
istration was sufﬁcient for therapy. This schedule is
effective likely due to rapid CD22 internalization without
Fig. 7 In vivo iPET images:
64Cu-DOTA-HB22.7 targets Raji
xenografts at 48 h after injection. Xenograft bearing mice were
injected IV, IP, or SQ with approximately 200 lCi of
64Cu-DOTA-
HB22.7. Mice were imaged using a micro-PET II at 48 h after
injection. n = 3 mice per injection route. Xenograft locations are
indicated by arrows. a IV injection. b IP injection. c SQ injection
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123return of CD22 to the cell surface for nearly 2 weeks due to
persisting HB22.7 levels. HB22.7 targets tumor equally
well by IV, SQ or IP administrations. Although the initial
biodistributions were different, all routes resulted in spe-
ciﬁc tumor targeting. When using mice as an experimental
model, it may be very convenient and provide a more
consistent dose in some experimental plans to give the
mAb SQ or IP. Finally, this is one of the ﬁrst studies to
conclusively demonstrate that the speciﬁc epitope bound
by an antibody has signiﬁcant therapeutic implications.
This knowledge also may enhance development of syner-
gistic drugs to be given with HB22.7.
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